Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Resistance to STI571 is an emerging problem for patients with chronic myelogenous leukemia (CML). Mutation in the kinase domain of Bcr-Abl is the predominant mechanism of the acquired resistance to STI571. In the present study, we investigated the effect of triptolide on cell survival or apoptosis in CML cells bearing Bcr-Abl-T315I or wild-type Bcr-Abl. Experimental Design: CML cell lines (KBM5 versus KBM5-T315I, BaF3-Bcr-Abl versus BaF3-Bcr-Abl-T315I) and primary cells from CML patients with clinical resistance to STI571 were treated with triptolide, and analyzed in terms of growth, apoptosis, and signal transduction. Nude mouse xenograft model was also used to evaluate the antitumor activity. Results: Triptolide potently down-regulated the mRNA and protein levels of Bcr-Abl independently of the caspase or proteosome activation in CML cells. It induced mitochondrial-dependent apoptosis in Bcr-Abl-T315I CML cells and primary cells from CML patients with clinical resistance to STI571. Additionally, triptolide inhibited the growth of STI571-sensitive KBM5 and STI571-resistant KBM5-T315I CML cells in nude mouse xenografts. Triptolide also down-regulated the expression of survivin, Mcl-1, and Akt in CML cells, which suggests that it may have multiple targets. Conclusions: These findings suggest that triptolide is a promising agent to overcome STI571-resistant CML cells, and warrant a clinical trial of triptolide derivatives for CML with Bcr-Abl-T315I mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Cited by
Triptolide: Progress on research in pharmacodynamics and toxicology
Li, X.-J., Jiang, Z.-Z., & Zhang, L.-Y. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.06.006 · Cited by 378
“, 2010), reducing Bcl-2 and Mcl-1 in chronic myelogenous leukemia cells (5–25 nM for 24 h) (Shi et al., 2009).”
BackgroundJin, Y., Lu, Z., Ding, K., Li, J., Du, X., Chen, C., Sun, X., Wu, Y., Zhou, J., & Pan, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3950 · Cited by 322
Self-citationZhou, Z.-L., Yang, Y.-X., Ding, J., Li, Y.-C., & Miao, Z.-H. (2012) · Natural Product Reports · doi:10.1039/c2np00088a · Cited by 312
Triptolide and Its Derivatives as Cancer Therapies
Noel, P., Von Hoff, D. D., Saluja, A. K., Velagapudi, M., Borazanci, E., & Han, H. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.03.002 · Cited by 294
Zhou, Z.-L., Luo, Z.-G., Yu, B., Jiang, Y., Chen, Y., Feng, J.-M., Dai, M., Tong, L.-J., Li, Z., Li, Y.-C., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-268 · Cited by 38
“Triptolide possesses broadspectrum anticancer, antiangiogenesis, and drugresistance circumvention activities [10-13].”
Background
Metadata
- Authors
- Shi, X., Jin, Y., Cheng, C., Zhang, H., Zou, W., Zheng, Q., Lu, Z., Chen, Q., Lai, Y., & Pan, J.
- Venue
- Clinical Cancer Research
- Published
- 2009-02-27
- Volume
- 15
- Issue
- 5
- Pages
- 1686-1697
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2170196149
- Cited by
- 115
- References
- 2
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-2141
- The paper
- Shi, X., Jin, Y., Cheng, C., Zhang, H., Zou, W., Zheng, Q., Lu, Z., Chen, Q., Lai, Y., & Pan, J. (2009). Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-2141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.